INT-1B3 triggers the transition from ‘cold-to-hot (immunoreactive)’ tumor, and activates the adaptive immune response.
In 2021, InteRNA Technologies initiated an open-label, multi-center, Phase 1a (dose escalation) clinical trial of INT-1B3 in ‘all-comer’ cancer patients with advanced solid tumors. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of INT-1B3, to help defining the Recommended Phase 2 Dose (RP2D).
Click here to learn more about the Phase 1a (dose escalation) trial (INT1B3-CLIN-101).
In our second independent oncology development program, INT-5A2 is a LNP-formulated, chemically-modified mimic of a tumor suppressor miRNA, comprising anti-proliferative and anti-angiogenic properties and serves as potential back-up compound for INT-1B3 in hepatocellular carcinoma (HCC), with in addition pre-clinical proof-of-concept in highly vascularized tumors like glioblastoma (GBM).
Yet, based on its MoA, targeting the pathways involved in the resistance to crizotinib (Xalkori®), we foresee initial straightforward clinical development in crizotinib-resistant ALK+ non-small cell lung cancer (NSCLC).
INT-2H10 represents our furthest advanced CNS program in which we obtained pre-clinical proof of concept in an established Kainate model for mesial Temporal Lobe Epilepsy (mTLE), the most common form of Epilepsy which is highly resistant and refractory to current treatments. INT-2H10 is an antimiR that knocks down a miRNA that is overexpressed in the brain of mTLE patients and thereby reducing the number, duration, and severity of spontaneous recurrent seizures at the chronic stage.
In addition to the above-mentioned programs, we are advancing a portfolio of early-stage programs.